Life Sciences Opportunities in India & China: From Innovation to Commercialization
September 30, 2009
China and India are emerging as major players in the life sciences industry. Both countries have a wealth of top talent as well as rapidly-improving resources for the industry. Both countries also constitute important current and potential markets for drugs, devices and diagnostics, and are also projected to be major sources of innovation in the not-too-distant future. This panel will explore the significant opportunities in China and India, in terms not only of expanding operations to both countries, but also in terms of working with innovative companies that originate from China and India.
Moderator:
- David A. Charapp, Special Counsel, Foley & Lardner LLP
Panelists:
- Stephen A. Bent, Partner, Foley & Lardner LLP
- Friedhelm Blobel, Ph.D., President, CEO, Director, SciClone Pharmaceuticals
- Kim Kamdar, Ph.D., Principal at Domain Associates
- Sanjay Shukla, M.D., M.S., Chief Executive Officer, RxMD
Related Insights
January 12, 2026
Energy Current
Ninth Circuit Hears Oral Argument in Challenge to California Climate Disclosure Laws SB 261 and SB 253; No Ruling Yet
On January 9, 2026, a three-judge panel for the U.S. Court of Appeals for the Ninth Circuit heard oral argument in a challenge to…
January 12, 2026
Labor & Employment Law Perspectives
Cannabis and Employment Law: The Year Ahead in 2026
As we move into 2026, legal frameworks surrounding cannabis continue to evolve across the jurisdictions in ways that can directly or…
January 12, 2026
Foley Viewpoints
How Chinese Utility Models Fit Into Global IP Strategies
Utility models have historically attracted less attention than conventional invention patents in multinational patent portfolio planning. Yet with an enduring and, in many cases, growing Chinese presence in key sectors including electric vehicles, batteries, semiconductors, renewables, clean tech and telecommunications, utility models are gaining renewed strategic relevance.